JP2001518792A - 血液製剤から希少細胞を採集する方法 - Google Patents
血液製剤から希少細胞を採集する方法Info
- Publication number
- JP2001518792A JP2001518792A JP54293298A JP54293298A JP2001518792A JP 2001518792 A JP2001518792 A JP 2001518792A JP 54293298 A JP54293298 A JP 54293298A JP 54293298 A JP54293298 A JP 54293298A JP 2001518792 A JP2001518792 A JP 2001518792A
- Authority
- JP
- Japan
- Prior art keywords
- porous medium
- rare cells
- cells
- population
- rare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010836 blood and blood product Substances 0.000 title claims abstract description 54
- 229940125691 blood product Drugs 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 126
- 239000003480 eluent Substances 0.000 claims abstract description 99
- 230000000717 retained effect Effects 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims description 334
- 239000002609 medium Substances 0.000 claims description 191
- 210000003714 granulocyte Anatomy 0.000 claims description 21
- 210000004698 lymphocyte Anatomy 0.000 claims description 21
- 238000010828 elution Methods 0.000 claims description 20
- 150000001768 cations Chemical class 0.000 claims description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 210000004443 dendritic cell Anatomy 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 210000001616 monocyte Anatomy 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 210000000265 leukocyte Anatomy 0.000 description 22
- 238000000926 separation method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 230000014759 maintenance of location Effects 0.000 description 13
- 239000012190 activator Substances 0.000 description 12
- 239000000306 component Substances 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 238000011010 flushing procedure Methods 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000002955 secretory cell Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 229920002292 Nylon 6 Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- YBLJYSTXRAWBBH-PZRMXXKTSA-N (2s,3r,4s,5r,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-PZRMXXKTSA-N 0.000 description 1
- YBLJYSTXRAWBBH-ZFYZTMLRSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-ZFYZTMLRSA-N 0.000 description 1
- YBLJYSTXRAWBBH-VEIUFWFVSA-N (2s,3s,4s,5s,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O YBLJYSTXRAWBBH-VEIUFWFVSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- -1 Cain Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 229920000572 Nylon 6/12 Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000018981 granulocyte chemotaxis Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記工程を含む、血液製剤から希少細胞の1集団を採集する方法: 希少細胞を含有する血液製剤を多孔質媒体と接触させ; 該希少細胞を該多孔質媒体上に選択的に保持し; 該多孔質媒体を富栄養溶離液と接触させ;そして 希少細胞の該集団を該多孔質媒体から選択的に溶離させる。 2.下記工程を含む、血液製剤から希少細胞を採集する方法: 該希少細胞を含有する血液製剤を多孔質媒体と接触させ; 該希少細胞を該多孔質媒体上に選択的に保持し; 該多孔質媒体を約5〜37℃の温度で溶離液と接触させ;そして 該第一表面から該希少細胞を選択的に溶離させる。 3.該溶離液が富栄養液体を含む、請求の範囲第2項記載の方法。 4.該溶離液がウシ血清アルブミンおよびクエン酸/塩−デキストロースを添加 したダルベッコ修飾イーグル培地を含む、請求の範囲第1項ないし第3項のいず れか1項に記載の方法。 5.該溶離液が緩衝剤含有食塩水を含む、請求の範囲第1項ないし第4項のいず れか1項に記載の方法。 6.該溶離液が約15〜35℃の範囲内の温度である、請求の範囲第1項ないし第5 項のいずれか1項に記載の方法。 7.該溶離液が約20〜30℃の範囲内の温度である請求の範囲第6項記載の方法。 8.多孔質媒体の溶離液との接触が、多孔質媒体を溶離液で逆流フラッシングす ることを含む、請求の範囲第1項ないし第7項のいずれか1項に記載の方法。 9.血液製剤が希少細胞の少なくとも第1および第2の集団を含み、希少細胞の 第1集団を選択的に溶離させ、希少細胞の第2集団は該溶離液との接触後も多孔 質媒体上に選択的に保持されたままである、請求の範囲第2項記載の方法。 10.該集団が希少細胞の第1集団であり、希少細胞の第2集団は該溶離液との接 触後も多孔質媒体上に選択的に保持されたままとなる、請求の範囲第1項または 第2項ないし第8項のいずれか1項に記載の方法。 11.該第1集団が本質的にリンパ球からなる請求の範囲第9項または第10項記載 の方法。 12.該第2集団が本質的に樹状細胞、顆粒球、単球、マクロファージ、または幹 細胞からなる、請求の範囲第10項または第11項記載の方法。 13.該溶離液が希少細胞の該第2集団の該多孔質媒体への選択的付着を促進する 、請求の範囲第10項ないし第12項のいずれか1項に記載の方法。 14.該溶離液が2価カチオンを含んでいる、請求の範囲第10項ないし第13項のい ずれか1項に記載の方法。 15.該溶離液がサイトカインを含んでいる、請求の範囲第10項ないし第14項のい ずれか1項に記載の方法。 16.該溶離液が少なくとも1種の補体複合体産物を含んでいる、請求の範囲第10 項ないし第15項のいずれか1項に記載の方法。 17.該補体複合体産物がC3a,C4a,およびC5aよりなる群から選ばれる、請求の 範囲第16項記載の方法。 18.希少細胞の該集団を含有する該溶離液を、第2の多孔質媒体と接触させ、該 希少細胞の1つの亜集団を該第2の多孔質媒体に選択的に保持する、請求の範囲 第1項ないし第17項のいずれか1項に記載の方法。 19.該第2の多孔質媒体が希少細胞の該亜集団に特異的な抗体を含んでいる、請 求の範囲第18項記載の方法。 20.該第2の多孔質媒体が該希少細胞の亜集団に結合するリガンドを含んでいる 、請求の範囲第18項または第19項記載の方法。 21.該亜集団が本質的に樹状細胞、顆粒球、単球、マクロファージ、または幹細 胞からなる、請求の範囲第18項ないし第20項のいずれか1項に記載の方法。 22.下記工程を含む、血液製剤から希少細胞を採集する方法: 該希少細胞を含有する該血液製剤を多孔質媒体と接触させ; 該希少細胞の第1および第2の集団を該多孔質媒体上に選択的に保持し; 希少細胞の該第1および第2の集団を、該第1集団が該第2集団に比べてより 強力に多孔質媒体に付着するのを促進させる因子と接触させ;そして 該多孔質媒体を、該第1および第2の集団と生理学的に適合性のある溶液を含 んでいる溶離液と接触させ、該希少細胞の該第2集団を希少細胞の該第1集団よ り大きな程度で該多孔質媒体から溶離させる。 23.該因子が該希少細胞の該第1集団により分泌される、請求の範囲第22項記載 の方法。 24.該因子がインターロイキン−IIである、請求の範囲第22項または第23項記載 の方法。 25.該多孔質媒体が該因子を含んでいる、請求の範囲第22項ないし第24項のいず れか1項に記載の方法。 26.該因子が抗体である、請求の範囲第22項ないし第25項のいずれか1項に記載 の方法。 27.該因子がリガンドである、請求の範囲第22項ないし第26項のいずれか1項に 記載の方法。 28.該因子がポリマーである、請求の範囲第25項記載の方法。 29.該ポリマーがナイロンである、請求の範囲第28項記載の方法。 30.希少細胞の該第1集団が、該溶離後に希少細胞の該第2集団由来の細胞を実 質的に含んでいない、請求の範囲第22項ないし第29項のいずれか1項に記載の方 法。 31.該第2集団がリンパ球を含んでいる、請求の範囲第22項ないし第30項のいず れか1項に記載の方法。 32.該第1集団が本質的に樹状細胞、顆粒球、単球、マクロファージ、または幹 細胞からなる、請求の範囲第22項ないし第31項のいずれか1項に記載の方法。 33.下記工程を含む、希少細胞の産物を得る方法: 希少細胞を含む血液製剤を、この希少細胞を選択的に保持する多孔質媒体と接 触させ、 該多孔質媒体を富栄養培養液と接触させて、該希少細胞の産物を産生するよう に該希少細胞の1集団を該孔質媒体上で培養し、 該培養液から該希少細胞の該産物を単離する。 34.該希少細胞がリンパ球を含んでいる、請求の範囲第1項ないし第8項または 第33項記載の方法。 35.該培養液がリンパ球を活性化する因子を含んでいる、請求の範囲第33項記載 の方法。 36.該希少細胞が幹細胞を含んでいる、請求の範囲第1項ないし第8項または第 33項記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4320097P | 1997-04-08 | 1997-04-08 | |
US60/043,200 | 1997-04-08 | ||
US6411197P | 1997-11-03 | 1997-11-03 | |
US60/064,111 | 1997-11-03 | ||
US6419297P | 1997-11-04 | 1997-11-04 | |
US60/064,192 | 1997-11-04 | ||
PCT/US1998/006643 WO1998045413A1 (en) | 1997-04-08 | 1998-04-03 | Method of harvesting rare cells from blood products |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001518792A true JP2001518792A (ja) | 2001-10-16 |
JP2001518792A5 JP2001518792A5 (ja) | 2005-11-10 |
JP4187275B2 JP4187275B2 (ja) | 2008-11-26 |
Family
ID=27366293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54293298A Expired - Lifetime JP4187275B2 (ja) | 1997-04-08 | 1998-04-03 | 血液製剤から希少細胞を採集する方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6544751B1 (ja) |
EP (2) | EP1690930A1 (ja) |
JP (1) | JP4187275B2 (ja) |
AT (1) | ATE329012T1 (ja) |
AU (1) | AU6795498A (ja) |
CA (1) | CA2286156C (ja) |
DE (1) | DE69834809T2 (ja) |
WO (1) | WO1998045413A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530691A (ja) * | 2004-03-29 | 2007-11-01 | スミス アンド ネフュー インコーポレーテッド | 生理溶液に由来する有核細胞及び/または血小板濃縮物の調製方法 |
WO2011001936A1 (ja) | 2009-06-30 | 2011-01-06 | 株式会社カネカ | 血液成分の分離システム、分離材 |
WO2012070622A1 (ja) | 2010-11-25 | 2012-05-31 | 株式会社カネカ | 白血球または単核球の分離方法、分離材 |
JP2012120458A (ja) * | 2010-12-06 | 2012-06-28 | Kaneka Corp | 細胞の分離器具。 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040224300A1 (en) * | 1997-01-24 | 2004-11-11 | Shuji Terashima | Method for separating nucleated cells |
JP4187275B2 (ja) * | 1997-04-08 | 2008-11-26 | ポール・コーポレーション | 血液製剤から希少細胞を採集する方法 |
US7745106B2 (en) * | 1997-06-24 | 2010-06-29 | Cascade Medical Enterprises, Llc | Methods and devices for separating liquid components |
US6979307B2 (en) * | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
WO2002083262A1 (en) * | 2001-04-10 | 2002-10-24 | Bioergonomics, Inc. | Cell separation compositions and methods |
US7074440B2 (en) * | 2002-05-01 | 2006-07-11 | Rulin Xiu | Compositions and methods for body weight loss |
US7695627B2 (en) * | 2002-06-19 | 2010-04-13 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for leukocyte enrichment |
US20050208501A1 (en) | 2004-03-16 | 2005-09-22 | Ambion, Inc. | Process and reagents for extraction of RNA from fractionated blood leukocytes |
US20060234210A1 (en) * | 2004-04-14 | 2006-10-19 | Affinergy, Inc. | Filtration device and method for removing selected materials from biological fluids |
WO2006029270A1 (en) * | 2004-09-07 | 2006-03-16 | Smith & Nephew, Inc. | Methods and devices for sterile field transfer |
US8308340B2 (en) * | 2004-11-23 | 2012-11-13 | Smith & Nephew, Inc. | Composite mixer |
CA2592381A1 (en) * | 2004-12-16 | 2006-06-22 | Idexx Laboratories, Inc. | Apparatus and method to elute microorganisms from a filter |
AU2006204858A1 (en) * | 2005-01-13 | 2006-07-20 | Perkinelmer Health Sciences, Inc. | Microfluidic rare cell detection device |
US8979770B2 (en) * | 2006-02-24 | 2015-03-17 | Merck Sharp & Dohme Corp. | Extraction and diagnostic fluid devices, systems and methods of use |
US7598089B2 (en) * | 2006-04-19 | 2009-10-06 | Bioe, Inc. | Methods and compositions for separating cells |
US7713688B2 (en) * | 2007-01-26 | 2010-05-11 | Bioe, Llc | Methods and compositions for depleting specific cell populations from blood tissues |
KR20090121297A (ko) | 2007-03-02 | 2009-11-25 | 스미쓰 앤드 네퓨 피엘씨 | 생물학적 시료의 여과시 초음파, 역세정 및 필터 이동에 의한 필터 세정용 기기 및 방법 |
US8158405B2 (en) * | 2008-06-30 | 2012-04-17 | General Electric Company | Process for concentrating and processing fluid samples |
US8546127B2 (en) * | 2008-06-30 | 2013-10-01 | General Electric Company | Bacteria/RNA extraction device |
US20100159506A1 (en) * | 2008-07-25 | 2010-06-24 | Cellscape Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
US8961787B2 (en) | 2008-12-01 | 2015-02-24 | General Electric Company | Systems and methods for processing complex biological materials |
US20100151438A1 (en) * | 2008-12-12 | 2010-06-17 | General Electric Company | Methods and kits for enhancing sedimentation and recovery of cells in a sample |
US20100210989A1 (en) | 2008-12-23 | 2010-08-19 | Janet Lesley Macpherson | Processing blood |
US9034280B2 (en) | 2009-12-16 | 2015-05-19 | General Electric Corporation | High-throughput methods and systems for processing biological materials |
EP2363501A1 (en) * | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
US20130143195A1 (en) | 2011-12-05 | 2013-06-06 | Pall Corporation | Leukocyte purification |
US9427512B2 (en) | 2012-06-08 | 2016-08-30 | Pall Corporation | Filter device |
US9421317B2 (en) | 2012-06-08 | 2016-08-23 | Pall Corporation | Cell harvesting device and system |
GB201306810D0 (en) | 2013-04-15 | 2013-05-29 | Cells4Life Group Llp | Methods of cell separation |
CA3007631A1 (en) | 2015-12-11 | 2017-06-15 | Research Institute At Nationwide Children's Hospital | Optimized patient specific non-linear tissue engineered vascular grafts |
US10940248B2 (en) * | 2016-12-19 | 2021-03-09 | Fenwal, Inc. | Systems and methods for recovering white blood cells from a leukoreduction filter |
US20230258663A9 (en) | 2019-05-02 | 2023-08-17 | Kellbenx Incorporated | Filtration-based methods for preparing fetal nucleated red blood cells (nrbcs) for diagnostic testing |
CN111454902B (zh) * | 2020-04-08 | 2022-12-02 | 郭华 | 血液分离富集白细胞、干细胞和/或病原体的方法及装置 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4070243A (en) * | 1976-08-30 | 1978-01-24 | University Of Illinois Foundation | Method for distinguishing subpopulations in a population of morphologically indistinguishable cells |
GB2018151B (en) | 1978-03-06 | 1982-12-08 | Asahi Chemical Ind | Seperation of leukocytes from leukocyte-containing suspension by filtration |
US4255267A (en) * | 1979-11-02 | 1981-03-10 | E. I. Du Pont De Nemours And Company | Separation and recovery of granulocytes from blood using adherence on an expandable bed of a polymeric material |
JPS57145662A (en) | 1981-03-02 | 1982-09-08 | Asahi Chemical Ind | Filter, method and apparatus for sampling white corpuscle component |
US4500509A (en) * | 1981-03-11 | 1985-02-19 | Lawrence Kass | Metachromatic dye sorption and fluorescent light emmisive means for differential determination of developmental stages of neutrophilic granulocytic cells and other leukocytes |
US4448879A (en) * | 1981-03-26 | 1984-05-15 | Hooper Trading Company | High yield process for in vitro production of serum-free and mitogen-free interleukin-2 |
US4645738A (en) * | 1983-09-30 | 1987-02-24 | Memorial Sloan-Kettering Institute Cancer Center | Method for differential diagnosis of T cell leukemias using monoclonal antibodies |
US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
JPS63127765A (ja) | 1986-11-17 | 1988-05-31 | テルモ株式会社 | 濾過器 |
US4923620A (en) | 1987-10-20 | 1990-05-08 | Pall Corporation | Device for depletion of the leukocyte content of blood and blood components |
EP0397403B1 (en) | 1989-05-09 | 1993-12-22 | Pall Corporation | Device and method for depletion of the leucocyte content of blood and blood components |
EP0406485A1 (en) | 1989-07-03 | 1991-01-09 | NPBI Nederlands Produktielaboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen B.V. | A method for the removal of leukocytes from a leukocyte-containing suspension and filter unit for use with the method |
US5258126A (en) | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
US5837539A (en) * | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
GB9026538D0 (en) | 1990-12-06 | 1991-01-23 | Knight Scient Ltd | Filtration arrangement |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
IL104670A (en) | 1993-02-09 | 1998-04-05 | Travenol Lab Israel Ltd | Leukocyte removal method and filter unit for same |
GB9307321D0 (en) | 1993-04-07 | 1993-06-02 | Knight Scient Ltd | Method of separating particles from a filter |
AU6773994A (en) * | 1993-04-23 | 1994-11-21 | Cellpro, Incorporated | Methods for enriching fetal progenitor cells from maternal blood |
WO1995017236A1 (en) | 1993-12-22 | 1995-06-29 | Baxter International Inc. | Filtration media and device for filtering leukocytes |
US5432054A (en) * | 1994-01-31 | 1995-07-11 | Applied Imaging | Method for separating rare cells from a population of cells |
US6001647A (en) * | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
US5972627A (en) * | 1994-06-15 | 1999-10-26 | Systemix, Inc. | Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby |
GB9413029D0 (en) * | 1994-06-29 | 1994-08-17 | Common Services Agency | Stem cell immobilisation |
US5789148A (en) * | 1994-08-31 | 1998-08-04 | Dendreon Corporation | Cell separation composition |
CA2198607C (en) | 1994-08-31 | 2000-04-18 | Peter Van Vlasselaer | Cell separation apparatus and method |
JPH08104643A (ja) * | 1994-10-05 | 1996-04-23 | Asahi Medical Co Ltd | 赤血球除去方法 |
US5647985A (en) | 1994-10-17 | 1997-07-15 | Baxter International Inc. | Whole blood leukodepletion and platelet filter |
US5662813A (en) * | 1994-10-21 | 1997-09-02 | Bioseparations, Inc. | Method for separation of nucleated fetal erythrocytes from maternal blood samples |
US5677136A (en) * | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5965457A (en) * | 1995-06-06 | 1999-10-12 | Magnani; John L. | Methods of screening for a candidate compound able to bind to CD34+ cells |
AU6223296A (en) * | 1995-06-07 | 1996-12-30 | Novartis Ag | Methods for obtaining compositions enriched for hematopoieti c stem cells and antibodies for use therein |
US6015554A (en) * | 1995-06-07 | 2000-01-18 | Systemix, Inc. | Method of reconstituting human lymphoid and dendritic cells |
US5891443A (en) * | 1995-07-03 | 1999-04-06 | The United States Of America As Represented By The Secretary Of Agriculture | Method to produce granulocyte colony stimulating factor from immortalized avian T lymphocytes to produce immortalized cells |
WO1997021488A1 (en) * | 1995-12-11 | 1997-06-19 | Dendreon Corporation | Cell separation composition, kit and method |
GB9603249D0 (en) * | 1996-02-16 | 1996-04-17 | Univ Nottingham | Foetal cell analysis |
JP3322595B2 (ja) * | 1996-03-28 | 2002-09-09 | テルモ株式会社 | フィルター装置および生体微細組織の分離・回収方法 |
WO1998005795A1 (en) * | 1996-08-02 | 1998-02-12 | The Center For Blood Research, Inc. | Enrichment of dendritic cells from blood |
ATE509094T1 (de) * | 1997-01-24 | 2011-05-15 | Asahi Kasei Kuraray Medical Co | Methode zur zelltrennung |
JP4187275B2 (ja) * | 1997-04-08 | 2008-11-26 | ポール・コーポレーション | 血液製剤から希少細胞を採集する方法 |
US6120474A (en) | 1997-12-15 | 2000-09-19 | Nissho Corporation | Blood component-recovering apparatus and a method for recovering blood components using the same |
US5989441A (en) * | 1997-12-22 | 1999-11-23 | Interferon Science, Inc. | Recovery of functional human leukocytes from recycled filters |
JP2001161352A (ja) | 1999-12-03 | 2001-06-19 | Asahi Medical Co Ltd | 生体組織再生用細胞の分離方法、生体組織再生用細胞及び生体組織再生用細胞分離装置 |
-
1998
- 1998-04-03 JP JP54293298A patent/JP4187275B2/ja not_active Expired - Lifetime
- 1998-04-03 WO PCT/US1998/006643 patent/WO1998045413A1/en active IP Right Grant
- 1998-04-03 EP EP06075344A patent/EP1690930A1/en not_active Withdrawn
- 1998-04-03 US US09/402,158 patent/US6544751B1/en not_active Expired - Lifetime
- 1998-04-03 AT AT98913392T patent/ATE329012T1/de active
- 1998-04-03 AU AU67954/98A patent/AU6795498A/en not_active Abandoned
- 1998-04-03 EP EP98913392A patent/EP0973873B1/en not_active Expired - Lifetime
- 1998-04-03 CA CA2286156A patent/CA2286156C/en not_active Expired - Lifetime
- 1998-04-03 DE DE69834809T patent/DE69834809T2/de not_active Expired - Lifetime
-
2003
- 2003-02-11 US US10/361,586 patent/US20030134417A1/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530691A (ja) * | 2004-03-29 | 2007-11-01 | スミス アンド ネフュー インコーポレーテッド | 生理溶液に由来する有核細胞及び/または血小板濃縮物の調製方法 |
WO2011001936A1 (ja) | 2009-06-30 | 2011-01-06 | 株式会社カネカ | 血液成分の分離システム、分離材 |
KR20120098403A (ko) | 2009-06-30 | 2012-09-05 | 가부시키가이샤 가네카 | 혈액 성분의 분리 시스템, 분리재 |
US9649424B2 (en) | 2009-06-30 | 2017-05-16 | Kaneka Corporation | Blood component separation system and separation material |
WO2012070622A1 (ja) | 2010-11-25 | 2012-05-31 | 株式会社カネカ | 白血球または単核球の分離方法、分離材 |
KR20180063346A (ko) | 2010-11-25 | 2018-06-11 | 가부시키가이샤 가네카 | 백혈구 또는 단핵구의 분리 방법, 분리재 |
JP2012120458A (ja) * | 2010-12-06 | 2012-06-28 | Kaneka Corp | 細胞の分離器具。 |
Also Published As
Publication number | Publication date |
---|---|
CA2286156C (en) | 2013-03-19 |
DE69834809D1 (de) | 2006-07-20 |
CA2286156A1 (en) | 1998-10-15 |
EP1690930A1 (en) | 2006-08-16 |
EP0973873A1 (en) | 2000-01-26 |
EP0973873B1 (en) | 2006-06-07 |
US20030134417A1 (en) | 2003-07-17 |
US6544751B1 (en) | 2003-04-08 |
DE69834809T2 (de) | 2007-05-16 |
JP4187275B2 (ja) | 2008-11-26 |
WO1998045413A1 (en) | 1998-10-15 |
AU6795498A (en) | 1998-10-30 |
ATE329012T1 (de) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4187275B2 (ja) | 血液製剤から希少細胞を採集する方法 | |
EP0987325B1 (en) | Method for separating cells | |
US5635387A (en) | Methods and device for culturing human hematopoietic cells and their precursors | |
TW200524647A (en) | Tangential flow filtration devices and methods for stem cell enrichment | |
JPH07503127A (ja) | 幹細胞を選択的に増加する方法 | |
US20040152190A1 (en) | Method of separating and concentrating cells for kidney regfneration | |
US7393628B2 (en) | Method for enriching adherent monocyte populations | |
US20020031757A1 (en) | Method of regenerating a tissue | |
US20030180705A1 (en) | Method of regenerating blood vessels | |
JP4245324B2 (ja) | 単球の分離回収方法 | |
JP3938973B2 (ja) | 細胞分離方法 | |
JPH07500597A (ja) | 移植用細胞の冷凍方法 | |
JPH09121849A (ja) | 細胞採取システムおよび細胞採取方法 | |
JP4043094B2 (ja) | 細胞分離器 | |
JP3945725B2 (ja) | 細胞分離方法 | |
KR100569609B1 (ko) | 세포면역치료제의 제조를 위한 림프구 장기 보관 방법 | |
JP2004121144A (ja) | 単核球の採取方法 | |
JP2000139454A (ja) | 細胞分離回収方法及び回収必要細胞含有液 | |
JPH09322758A (ja) | 体外増幅に適した細胞分離システムおよび分離方法 | |
Hyllner | Prestorage leucocyte filtration of blood: effects on cytokine generation and complement activation | |
JP2000325071A (ja) | 細胞分離回収方法 | |
US20040224300A1 (en) | Method for separating nucleated cells | |
Zwaan | Haemopoietic progenitor cells in human peripheral blood | |
Gant et al. | A novel leucocyte-depleting filter for use in continuous venovenous haemofiltration: preliminary in vitro studies | |
JP2003210161A (ja) | 肝幹細胞の濃縮器及び肝臓疾患の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070911 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070925 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071114 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080626 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080812 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080909 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120919 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130919 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |